Barbara D Reed1, Sioban D Harlow2, Melissa A Plegue1, Ananda Sen1,3. 1. 1 Department Family Medicine, University of Michigan , Ann Arbor, Michigan. 2. 2 Department of Epidemiology, School of Public Health, University of Michigan , Ann Arbor, Michigan. 3. 3 Department of Biostatistics, School of Public Health, University of Michigan , Ann Arbor, Michigan.
Abstract
BACKGROUND: Vulvodynia has been considered to be a chronic disorder. We sought to estimate the probability of and risk factors for remission, relapse, and persistence among women screening positive for vulvodynia. METHODS: Survey-based assessment in a longitudinal population-based study of women (the Woman to Woman Health Study) who screened positive for vulvodynia and completed at least four follow-up surveys. Outcome measures included remission without relapse, relapse (after remission), and persistence of a positive vulvodynia screen. Multinomial regression was used to assess factors associated with outcomes. RESULTS: Of 441 women screening positive for vulvodynia during the study, 239 completed 4 additional surveys. Of these, 23 (9.6%) had consistently positive vulvodynia screens, 121 (50.6%) remitted without relapse, and 95 (39.7%) relapsed following remission. Overall, factors associated with both relapse and persistence (compared with remission alone) included increased severity of pain ever (p < 0.001) or after intercourse (p = 0.03), longer duration of symptoms (p ≤ 0.001), and screening positive for fibromyalgia (p < 0.001). Factors associated with persistence (but not relapse) included more severe symptoms with intercourse (p = 0.001) and pain with oral sex (p = 0.003) or partner touch (p = 0.04). Factors associated with relapse (but not persistence) included having provoked pain (p = 0.001) or screening positive for interstitial cystitis (p = 0.05) at first positive vulvodynia screen. Demographic characteristics, age at pain onset, and whether vulvodynia was primary or secondary did not predict outcome. CONCLUSION: Remission of vulvodynia symptoms is common with approximately half of remitters experiencing a relapse within 6-30 months. Persistence without remission is the exception rather than the rule. Pain history and comorbid conditions were associated with the more severe outcomes of relapse and/or persistence compared with those who remitted only. These findings provide further support that vulvodynia is heterogeneous and often occurs in an episodic pattern.
BACKGROUND:Vulvodynia has been considered to be a chronic disorder. We sought to estimate the probability of and risk factors for remission, relapse, and persistence among women screening positive for vulvodynia. METHODS: Survey-based assessment in a longitudinal population-based study of women (the Woman to Woman Health Study) who screened positive for vulvodynia and completed at least four follow-up surveys. Outcome measures included remission without relapse, relapse (after remission), and persistence of a positive vulvodynia screen. Multinomial regression was used to assess factors associated with outcomes. RESULTS: Of 441 women screening positive for vulvodynia during the study, 239 completed 4 additional surveys. Of these, 23 (9.6%) had consistently positive vulvodynia screens, 121 (50.6%) remitted without relapse, and 95 (39.7%) relapsed following remission. Overall, factors associated with both relapse and persistence (compared with remission alone) included increased severity of pain ever (p < 0.001) or after intercourse (p = 0.03), longer duration of symptoms (p ≤ 0.001), and screening positive for fibromyalgia (p < 0.001). Factors associated with persistence (but not relapse) included more severe symptoms with intercourse (p = 0.001) and pain with oral sex (p = 0.003) or partner touch (p = 0.04). Factors associated with relapse (but not persistence) included having provoked pain (p = 0.001) or screening positive for interstitial cystitis (p = 0.05) at first positive vulvodynia screen. Demographic characteristics, age at pain onset, and whether vulvodynia was primary or secondary did not predict outcome. CONCLUSION: Remission of vulvodynia symptoms is common with approximately half of remitters experiencing a relapse within 6-30 months. Persistence without remission is the exception rather than the rule. Pain history and comorbid conditions were associated with the more severe outcomes of relapse and/or persistence compared with those who remitted only. These findings provide further support that vulvodynia is heterogeneous and often occurs in an episodic pattern.
Authors: D Nunns; D Mandal; M Byrne; J McLelland; R Rani; J Cullimore; D Bansal; F Brackenbury; G Kirtschig; M Wier Journal: Br J Dermatol Date: 2010-03-16 Impact factor: 9.302
Authors: M McKay; O Frankman; B J Horowitz; C Lecart; L Micheletti; C M Ridley; M L Turner; J D Woodruff Journal: J Reprod Med Date: 1991-06 Impact factor: 0.142
Authors: Hope K Haefner; Michael E Collins; Gordon D Davis; Libby Edwards; David C Foster; Elizabeth Dee Heaton Hartmann; Raymond H Kaufman; Peter J Lynch; Lynette J Margesson; Micheline Moyal-Barracco; Claudia K Piper; Barbara D Reed; Elizabeth G Stewart; Edward J Wilkinson Journal: J Low Genit Tract Dis Date: 2005-01 Impact factor: 1.925
Authors: Barbara Gardella; Daniele Porru; Rossella E Nappi; Maria Diletta Daccò; Alessia Chiesa; Arsenio Spinillo Journal: J Sex Med Date: 2011-04-07 Impact factor: 3.802
Authors: Jocelyn T Sutton; Gloria A Bachmann; Lauren D Arnold; George G Rhoads; Raymond C Rosen Journal: J Womens Health (Larchmt) Date: 2008-10 Impact factor: 2.681
Authors: Barbara D Reed; Siobán D Harlow; Ananda Sen; Rayna M Edwards; Di Chen; Hope K Haefner Journal: Obstet Gynecol Date: 2012-07 Impact factor: 7.661
Authors: M J Tribó; O Andión; S Ros; M Gilaberte; F Gallardo; A Toll; M Ferrán; A Bulbena; R M Pujol; J E Baños Journal: Dermatology Date: 2008 Impact factor: 5.366
Authors: Arpana Gupta; Davis C Woodworth; Benjamin M Ellingson; Andrea J Rapkin; Bruce Naliboff; Lisa A Kilpatrick; Jean Stains; Salome Masghati; Kirsten Tillisch; Emeran A Mayer; Jennifer S Labus Journal: J Pain Date: 2018-01-31 Impact factor: 5.820
Authors: Barbara D Reed; Ananda Sen; Sioban D Harlow; Hope K Haefner; Richard H Gracely Journal: J Low Genit Tract Dis Date: 2017-01 Impact factor: 1.925
Authors: Barbara D Reed; Kimberly S McKee; Melissa A Plegue; Sung Kyun Park; Hope K Haefner; Sioban D Harlow Journal: J Womens Health (Larchmt) Date: 2018-10-10 Impact factor: 2.681